

TABLE OF CONTENTS

March 16, 2009

No. 2131

BUSINESS

- 1 Acquisition of Wyeth to Make Pfizer No. 1 in Japan: Mr Iwasaki
- 4 or 5 New Products to Be Approved in 2009
- Ethical Drug Sales Down 2%
- 2 Nippon Shinyaku Licenses Prulifloxacin to Lee's Pharma in China
- 3 Teijin, Nissan Chemical License NTC-801 to BMS
- 3 Bristol-Myers to Promote Sprycel with Over 200 MRs
- Difficult to Choose Between Sprycel and Tasigna
- 4 2008 Ethical Drug Market in Japan Totaled ¥8,254.3 Bil. on NHI Price Basis: IMS
- Antineoplastics Become 2nd Largest Therapeutic Category
- 6 Astellas Files Lawsuit against CVT
- 6 Olmetec Remains No. 1 for 2nd Month Running on Both GP and HP Markets: Rep Track Survey
- 8 **Commentary**
- Large Hospital Groups Move to Joint Purchases
- 9 Nat'l Univ. Hospitals to Consider Joint Purchase of Drugs
- 9 **BUSINESS NEWS IN BRIEF**
- Pfizer Ties Up with Bausch & Lomb for Ophthalmic Products
- Pfizer Ties Up with Aurobindo of India for Generics
- Sanofi-aventis Acquires Czech Generic Company
- QOL Aims at Sales of ¥67.4 Bil. in 3 Years

REGULATORY

- 10 FDA to Require New Clinical Data on Alogliptin: Takeda
- Approval May Be Delayed by 2 Years
- 11 Clozaril Recommended for Approval under Strict Monitoring System
- Micombi Combination Tablet also Recommended for Approval
- Teva's Glatiramer Recommended as Orphan Drug
- 12 Mr Toda Warns Consumers against Counterfeit Drugs Sold Via Internet

GENERICS

- 14 Shasun to Enhance Its Presence in Japan via Its Subsidiary in Tokyo
- 14 Guidance on Biosimilars Issued by Korosho
- Large Abbreviations Possible in Non-Clinical, Clinical Studies

- 15 *Chuikyo* Subcommittee Discusses Pros and Cons of "Generics Coefficient"
- 16 3 More National Medical Centers Publish Lists of Generics They Use

R&D

- 16 Council Proposes Nat'l Project to Quickly Develop Unapproved Drugs
- 17 Studies on Ethnic Differences between Japan, China and South Korea Progress
- 17 Cancer Treatment Using Unapproved Peptide Vaccine Applied for as Advanced Medical Technology
- 18 More Objective Endpoints Needed for Allergic Rhinitis Treatments
- 18 **R&D NEWS IN BRIEF**
- Takeda Initiates 2 PII Trials of MLN8237 Abroad
- FDA Approves PIII Study Design for Collategene: AnGes MG
- Zeria to Consult EMEA to Accelerate Development of Z-338
- ASP8825/XP13512 Improves RLS in PII Trial: Astellas
- Astellas Gives Up Development of ASP2314/ACR-16
- JCROA to Introduce Monitor Certification System
- LDP's Commission Aims at Legislation to Commercialize R&D Results Sooner

TOPICS

- 20 **TOPICS**
- Unexpected Demand for ActHIB Causes Shortage of Supply

MEDICAL DEVICES

- 21 Ortho-K Recommended for Approval
- Endeavor Coronary Stent as Well
- Terumo's Artificial Heart Recommended as Orphan Medical Device
- 21 Takara Bio to Launch Reagent to Prepare Human iPS Cells

SELF-MEDICATION

- 22 New Sales System May Adversely Affect Business in Short Term: Mr Yamada of Rohto
- 22 Diclofenac-Based OTC Drugs Recommended for Approval
- 22 Pro-Online Sale Parties Exchange Opinions
- JODA Sends Open Letter to Health Minister

MEDICAL FACILITIES & NURSING CARE

- 23 Amended Hypertension Management GL Discussed at JHF Workshop